Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lutetium-DOTATATE

#4220

Introduction: 177Lutetium (Lu)-DOTATATE is an effective treatment for metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, radiation can cause transient inflammation/swelling of tumors which can result in toxicity. Treatment-related small bowel obstruction associated with mesenteric or peritoneal disease has been described.

Aim(s): We investigated the potential for intestinal ischemia in 177Lu-DOTATATE treated patients.

Materials and methods: Clinical records of patients with GEP-NETs treated with 177Lu-DOTATATE at our institution between April 2018 and December 2022 were reviewed.

Conference:

Presenting Author:

Authors: Pelle E, Al-Toubah T, El-Haddad G, Strosberg J,

Keywords: PRRT, Acute bowel ischemia, mesenteric metastasis,